Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating on Sarepta Therapeutics, maintaining a price target of $152.
September 20, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Sarepta Therapeutics, keeping the price target at $152. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the price target at $152 by Cantor Fitzgerald indicates that the analyst does not foresee significant changes in the stock's performance in the short term. This suggests stability in the stock's valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100